SecBot SecBot
SECBOTREPLAY Home › Report › FATE

FATE · Fate Therapeutics reported Q1 2026 results with a net loss of $0.26 per…

FATE THERAPEUTICS INC · 8-K filed May 13, 2026 at 08:32 ET

At the news

NEUTRALIMPACT 5/10

8-K filed May 13, 2026 at 08:32 ET

Fate Therapeutics reported Q1 2026 results with a net loss of $0.26 per share, slightly narrower than the $0.32 loss in Q1 2025, and revenue of $1.3M from its Ono collaboration. The key catalysts are regulatory and clinical: FT819 was selected for the FDA's CDRP program, the Phase 2 RECLAIM-LN trial is on track for H2 2026, and the operating runway was extended into 2028 with $174.8M in cash. However, the company remains a pre-revenue clinical-stage biotech with no approved products and a net loss of $31.2M for the quarter.

  • Cash, cash equivalents, and investments of $174.8M as of March 31, 2026, providing runway into 2028
  • Net loss of $31.2M for Q1 2026, improved from $37.6M loss in Q1 2025
  • Revenue of $1.3M from Ono Pharmaceutical collaboration, down from $1.6M in Q1 2025
  • FT819 selected for FDA's CDRP program, potentially accelerating regulatory pathway

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access